Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAO10K)

Drug Name

PF-07799544 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Mitogen-activated protein kinase (MAPK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GBL-310	DM2IFJQ	Keratosis	ED56	Phase 2	[3]
LTT462	DM94E6W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[5]
Bidentate ligands of Markush derivative 2	DM2QNMC	N. A.	N. A.	Patented	[6]
Bidentate ligands of Markush derivative 1	DMB08D3	N. A.	N. A.	Patented	[6]
PMID25991433-Compound-Q1	DMEMSB2	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-C3	DMSKWBE	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-J6	DMOWULJ	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L	DM5U8WT	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mitogen-activated protein kinase (MAPK)	TTVOE6D	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05538130) A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
3	WO patent application no. 2010,0456,51, Methods for analyzing drug response.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
6	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.